Your browser doesn't support javascript.
loading
Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria.
Pejaver, Vikas; Byrne, Alicia B; Feng, Bing-Jian; Pagel, Kymberleigh A; Mooney, Sean D; Karchin, Rachel; O'Donnell-Luria, Anne; Harrison, Steven M; Tavtigian, Sean V; Greenblatt, Marc S; Biesecker, Leslie G; Radivojac, Predrag; Brenner, Steven E.
Afiliação
  • Pejaver V; Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Biomedical Informatics and Medical Education, University of Washington, Seattle
  • Byrne AB; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Feng BJ; Department of Dermatology, University of Utah, Salt Lake City, UT 84132, USA; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
  • Pagel KA; The Institute for Computational Medicine, The Johns Hopkins University, Baltimore, MD 21218, USA.
  • Mooney SD; Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA 98195, USA.
  • Karchin R; The Institute for Computational Medicine, The Johns Hopkins University, Baltimore, MD 21218, USA; Departments of Biomedical Engineering, Oncology, and Computer Science, The Johns Hopkins University, Baltimore, MD 21218, USA.
  • O'Donnell-Luria A; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, USA; Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
  • Harrison SM; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Ambry Genetics, Aliso Viejo, CA 92656, USA.
  • Tavtigian SV; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
  • Greenblatt MS; Department of Medicine and University of Vermont Cancer Center, University of Vermont, Larner College of Medicine, Burlington, VT 05405, USA.
  • Biesecker LG; Center for Precision Health Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Radivojac P; Khoury College of Computer Sciences, Northeastern University, Boston, MA 02115, USA. Electronic address: predrag@northeastern.edu.
  • Brenner SE; Department of Plant and Microbial Biology and Center for Computational Biology, University of California, Berkeley, Berkeley, CA 94720, USA. Electronic address: brenner@compbio.berkeley.edu.
Am J Hum Genet ; 109(12): 2163-2177, 2022 12 01.
Article em En | MEDLINE | ID: mdl-36413997
ABSTRACT
Recommendations from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) for interpreting sequence variants specify the use of computational predictors as "supporting" level of evidence for pathogenicity or benignity using criteria PP3 and BP4, respectively. However, score intervals defined by tool developers, and ACMG/AMP recommendations that require the consensus of multiple predictors, lack quantitative support. Previously, we described a probabilistic framework that quantified the strengths of evidence (supporting, moderate, strong, very strong) within ACMG/AMP recommendations. We have extended this framework to computational predictors and introduce a new standard that converts a tool's scores to PP3 and BP4 evidence strengths. Our approach is based on estimating the local positive predictive value and can calibrate any computational tool or other continuous-scale evidence on any variant type. We estimate thresholds (score intervals) corresponding to each strength of evidence for pathogenicity and benignity for thirteen missense variant interpretation tools, using carefully assembled independent data sets. Most tools achieved supporting evidence level for both pathogenic and benign classification using newly established thresholds. Multiple tools reached score thresholds justifying moderate and several reached strong evidence levels. One tool reached very strong evidence level for benign classification on some variants. Based on these findings, we provide recommendations for evidence-based revisions of the PP3 and BP4 ACMG/AMP criteria using individual tools and future assessment of computational methods for clinical interpretation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Calibragem Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Am J Hum Genet Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Calibragem Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Am J Hum Genet Ano de publicação: 2022 Tipo de documento: Article